Overview

An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Study of Biweekly Docetaxel plus Androgen-Deprivation Therapy (ADT) in Patients with Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Androgens
Docetaxel